Table 2 Comparison of the first examination results between patients with antiviral drugs and patients without antiviral drugs during the follow-up in our hospital

Patients

527

268

598

161

324

36

Age, years

38.1 ± 10.0

36.6 ± 10.7 ^NSa ‡

38.5 ± 9.0 ^NSab

37.5 ± 8.8 ^NSabc

36.8 ± 10.1 ^NSabcd

37.1 ± 10.1 ^NSabcde

0.098

Male, n (%)

344 (65.3)

183 (68.3) ^NSa

437 (73.1) ^NSab

120 (74.5) ^NSabc

223 (68.8) ^NSabcd

27 (75.0) ^NSabcde

0.057

BMI, kg/m²

22.2 (19.9.,25.0)

21.8 (19.4,24.1) *a

22.4 (20.6,24.6) ^Nsa, *b

23.0 (21.4,23.9) ^NSabc

22.2 (19.7,24.2) ^NSabd, *c

23.2 (22.0,24.1) ^NSabcde

0.028

History of HBV, years

10 (7,20)

10 (8,15) ^NSa

10 (7,20) *a, **b

10 (6,20) ^NSabc

10 (7,20) ^NSabd, *c

10 (6,20) ^NSabcde

0.005

NAFLD, n (%)

90 (17.1)

30 (11.2) ^NSa

80 (13.4) ^NSab

16 (9.9) ^NSabc

49 (15.1) ^NSabcd

3 (8.3) ^NSabcde

0.088

T2DM, n (%)

11 (2.1)

7 (2.6) ^NSa

31 (5.2) ^NSab

8 (5.0) ^NSabc

12 (3.7) ^NSabcd

2 (5.6) ^NSabcde

0.091

Hepatitis B Virology

Log10 HBVDNA, IU/mL

2 (2,5)

4 (2,7) **a

4 (2,5) *a, **b

5 (3,7) **ac, *b

5 (2,7) **ac, *b, ^NSd

6 (5,7) **ac, *b, ^NSde

 < 0.001

Log10 HBsAg quantification, IU/mL

3 (2,4)

4 (3,4) **a

3 (3,4) *a, **b

3 (3,4) *ab, ^NSc

4 (3,5) **acd, *b

4 (3,4) **a, *c, ^NSbde

 < 0.001

HBeAg-positive, n (%)

127 (24.1)

171 (63.8) **a

278 (46.5) **ab

79 (49.1) *ab, ^NSc

190 (58.6) **ac, ^NSb, *d

19 (52.8) **a, ^NSbcde

 < 0.001

Biochemistry

ALT, U/L

28 (20,39)

44 (26,80) *a

35 (25,57) *a,^NSb

84 (46,370) **abc

39 (26,71) *a, ^NSbc, **d

170 (56,572) **abcde

 < 0.001

AST, U/L

26 (22,34)

33 (27,63) *a

32 (25,48) *a,^NSb

95 (58,217) **abc

34 (25,58) *a, ^NSbc, **d

137 (54,336) **abce, *d

 < 0.001

GGT, U/L

21 (16,37)

26 (18,42) ^NSa

29 (20,52) ^NSab

92 (54,174) ^NSabc

25 (19,43) ^NSabcd

89 (54,118) ^NSabcde

0.089

Alkaline phosphatase, U/L

71 (62,85)

82 (67,101) ^NSa

75 (66,90) *a,^NSb

102 (81,134) **abc

74 (65,83) ^NSabc, **d

97 (75,110) *ade, ^NSbc

 < 0.001

ALB, U/L

45.0 (43.0,47.5)

44.8 (42.7,46.7) ^NSa

44.5 (42.3.46.8) *a,^NSb

41.6 (37.2,44.0) **abc

44.7 (42.1,46.5) ^NSabc, **d

41.5 (39.1,44.3) *a, ^NSbcde

 < 0.001

GLB, U/L

29.3 (26.5,32.3)

29.9 (28.0,33.7) ^NSa

28.8 (26.1,31.9) ^NSab

33.6 (30.4,36.6) *ac, ^NSb

29.2 (26.2,32.1) ^NSabc, *d

32.9 (28.4,35.0) ^NSabcde

0.014

Total bilirubin, umol/L

13.5 (10.2,17.3)

13.5 (10.4,18.9) ^NSa

15.0 (11.8,20.1) ^NSab

20.3 (16.2,30.6) **abc

14.2 (10.9,18.8) ^NSabc, **d

18.9 (16.1,26.7) *abcde

 < 0.001

Direct bilirubin, umol/L

2.7 (3.1,3.7)

2.9 (2.0,4.2) ^NSa

3.0 (2.3,4.8) ^NSab

6.1 (3.9,10.6) **abc

2.9 (2.1,4.2) ^NSabc, **d

4.7 (3.8,10.8) *abcde

 < 0.001

PLT, 10^9/L

224 (190,259)

199 (167,263) ^NSa

193 (151,233) **ab

147 (108,178) **abc

215 (164,250) *ab, **cd

168 (114,200) *ab, ^NScd, **e

 < 0.001

LSM with SWE, kPa

5.7 (4.9,6.3)

6.7 (5.8,8.0) *a

6.8 (5.6,9.3) **ab

15.0 (6.9,15.6) **abc

6.0 (5.2,8.1) *a, ^NSb, **cd

12.9 (8.8,17.0) **abce, *d

 < 0.001

AFP, ng/mL

2.3 (1.7,3.4)

3.0 (2.0,4.7) ^NSa

3.1 (2.3,5.1) ^NSab

61.0 (35.8,216) **ac, *b

2.7 (2.0,3.8) ^NSabc, *d

79.5 (32.8,147.8) ^NSabcde

0.006

Cirrhosis, n(%)

29 (5.5)

33 (12.3) *a

179 (29.9) **ab

125 (77.6) **abc

72 (22.2) **ad, *bc

30 (83.3) **abce, ^NSd

 < 0.001

REACH-B score

5.7 ± 3.0

7.4 ± 3.0 **a

8.2 ± 3.5 **ab

10.6 ± 3.1 **abc

8.0 ± 3.0 **ad, *b, ^NSc

9.1 ± 2.8 **a, *bde, ^NSc

 < 0.001

Page-B score

12.1 ± 5.6

13.0 ± 5.6 ^NSa

16.9 ± 5.9 **ab

20.2 ± 5.9 **abc

14.2 ± 5.5 **acd, *b

16.7 ± 5.1 **ab, *de, ^NSc

 < 0.001

mPage-B score

7.0 ± 3.4

6.1 ± 3.7 *a

9.6 ± 3.6 **ab

11.5 ± 3.8 **abc

6.6 ± 3.5 **cd, ^NSab

6.1 ± 3.7 **bd, *ae, ^NSc

 < 0.001

aMAP score

44.7 ± 8.2

43.3 ± 8.6 ^NSa

51.1 ± 8.9 **ab

56.7 ± 8.7 **abc

43.9 ± 8.5 **cd, ^NSab

50.8 ± 6.1 **abde, ^NSc

 < 0.001